Q-omics provides the consensus-scored KRT222 profile across patient tissues and cancer cell-line models. KRT222 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KRT222 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, KRT222 RNA expression shows 16,204 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where KRT222 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT222 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT222 survival associations across molecular data types. KRT222 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT222 RNA expression–survival associations across cancer types. High KRT222 expression shows unfavorable associations in UVM and KIRC, but favorable associations in LUAD, LGG, ESCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UVM as the clearest survival context for KRT222 RNA expression.
This table summarizes KRT222 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT222. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT222 shows lower tumor expression in BLCA, HNSC, KICH, KIRC, COAD and LUAD. The BLCA box plot shows higher KRT222 RNA expression in normal versus tumor tissue (log2 FC = −0.493, t-test p < 0.001).
This table shows molecular features associated with KRT222 in patient tissues and cancer cell lines. In patient samples, KRT222 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT222 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_SCLC.
